Zurich-Schlieren, September 19, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs known as DARPin® therapies, is hosting an R&D update on “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics.” The event takes place in New York on November 9, 2017, 12.00-2.30 pm EDT.
The meeting will feature a presentation by C. David Nicholson, Executive Vice President & Chief R&D Officer at Allergan, who will discuss the company’s wet AMD candidate, abicipar.
The meeting will also feature presentations by key opinion leaders (KOLs) demonstrating the potential of DARPin® therapeutics in oncology (see full bios below):
- Prof. Angelo Vacca, MD - Multiple Myeloma (MM)
- Prof. Kathryn A. Gold, MD - Non-Small Cell Lung Cancer (NSCLC)
- Dr. Richard Baird, MA MBBS FRCP Ph.D. - HER2+ Breast Cancer
Molecular Partners’ management team will provide an overview of the Company’s clinical oncology pipeline and present key data from its pre-clinical immuno-oncology activities.
Schedule for Thursday, November 9, 2017
- 11:45 am EDT Check-In
- 12:00 pm EDT Lunch to begin
- 12:15 – 2:30 pm EDT Presentations and Q&A
Aretsky’s Patroon Townhouse
160 E. 46th Street, Between Lex and 3rd Ave.
New York, NY
Discussion topics will include:
- The DARPin® Platform and Corporate Strategy
- MP0250 phase 2 in MM
- MP0250 for NSCLC
- MP0274 for HER2+ tumors
- Immuno-oncology – with a focus on tumor-restricted agonists
- Abicipar, licensed to Allergan, currently in phase 3 trials for wet age-related macular degeneration (wet AMD). Topline results are expected in 2018.
- Updates on Molecular Partners’ clinical development timelines.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.
For those who are unable to attend in person, a live webcast and replay will be accessible on the company’s website.
Guest Speaker and KOL Biographies:
C. David Nicholson is Executive Vice President & Chief R&D Officer at Allergan. He holds degrees in pharmacology, earning his B.Sc. from the University of Manchester and his Ph.D. from the University of Wales. His prior pharmaceutical industry experience includes Beecham-Wülfing in Germany and various positions of increasing seniority at Organon, a Business Unit of Akzo Nobel, in the UK, the Netherlands, and the US. Ultimately, he became Executive Vice President, Research & Development, and a member of the Organon Executive Management Committee. He has also worked for Schering-Plough as Senior Vice President, responsible for global project management and drug safety, and at Merck as Senior Vice President, Licensing and Knowledge Management. As an integration team member, he played a key role in the strategic mergers of Organon BioSciences and Schering-Plough, as well as the acquisition of Schering-Plough by Merck and Forest Laboratories by Actavis. David Nicholson was also head of R&D and a member of the executive committee at Bayer Crop Science. He has served on the boards of several biotechnology companies, including Actinium Pharmaceuticals.
Angelo Vacca is Chief of Internal Medicine at the University of Bari Medical School, Bari (Italy), and also serves as its Vice-Rector and full professor. He is head of the lab “Angiogenesis, Vascular Biology, and Myeloma microenvironment.” Dr. Vacca is also honorary President of the Italian Society of Immunology, Clinical Immunology and Allergology. He completed his post-doctoral fellowship in clinical immunology at the University of Bari, and was awarded his M.D. degree in 1980. In 1983, began to specialize in hematology, and in 1993, in internal medicine. He spent three years at the Ludwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges S./Lausanne, Switzerland, focusing on the production of monoclonal antibodies, as well as immunoscintigraphy of and vascular access to human lymphomas. His current research fields include: angiogenesis and tumor progression (study of microvessel areas in tumors as progression marker; correlation with invasion and metastasis; bone marrow angiogenesis and myeloma progression; mechanisms of induction of angiogenesis); multiple myeloma and related malignancies (clinical, cellular and immunochemical features; polycenter, controlled chemotherapy studies). Dr. Vacca has published over 300 papers in international medical journals and has authored numerous reviews and book chapters. Dr. Vacca has been recognized with the Associazione Italiana per la Ricerca sul Cancro (Milan, Italy) award for his research.
Kathryn A. Gold, MD, is an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California San Diego Moores Cancer Center. She is the Associate Director of Clinical Research Services at the Altman Clinical and Translational Research Institute and the chair of the Moores Cancer Center Data and Safety Monitoring Committee. Dr. Gold is an active clinical and translational researcher, with a focus on the use of targeted therapies for the treatment of lung and head and neck cancers, in addition to running a successful clinical practice. Dr. Gold’s research has appeared in the New England Journal of Medicine, Science, and Journal of Clinical Oncology and has been presented at national and international meetings. She served as the principal investigator of a number of pharmaceutical sponsored and investigator initiated studies and has received grant support from the National Institutes of Health and the American Society of Clinical Oncology Conquer Cancer Foundation.
Dr. Richard Baird, MA MBBS FRCP Ph.D., is an Academic Consultant in Experimental Cancer Therapeutics at the University of Cambridge. He is also a cancer researcher and medical oncologist at Cambridge University Hospitals, U.K. He trained at University of Cambridge and Institute of Cancer Research / Royal Marsden Hospital. Dr. Baird holds a Ph.D. in molecular pharmacology and cancer drug development and specializes in the care of breast cancer patients. Dr. Baird’s research is focused on the development of novel HER2-targeted therapies, including better approaches for patients with brain metastases, as well as companion biomarkers to identify patients most likely to respond to treatment (or not) – including liquid biopsies / circulating tumor DNA. Since 2002 he has served as co- or principal investigator on more than 80 phase 1 / 2 clinical trials, and is currently the chief investigator on three multi-center investigator-initiated clinical trials. He is the UK national academic lead for the Association of Cancer Physicians.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the
passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details please contact:
Dr. Patrick Amstutz, CEO
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 43 344 42 42
Susan A. Noonan
S.A. Noonan Communications, LLC
Tel: +1 212 966 3650